Sunrise Technologies goes for liquidation
This article was originally published in Clinica
Executive Summary
Menlo Park, California-based Sunrise Technologies International, manufacturer of refractive surgery technology, has opted for Chapter 7 bankruptcy and will liquidate its assets. The decision, taken last week, comes a year after the company defaulted on a $1m loan repayment (see Clinica No 998, p 17). The company, which produces the holmium Yag laser, treatment with which involves shrinking the collagen around the eyeball, has had to make a series of layoffs in the last year in the wake of mixed reviews for its technology.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.